F M Muggia

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation
    F M Muggia
    Department of Radiology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
    J Clin Oncol 15:987-93. 1997
  2. ncbi Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome
    T Safra
    Department of Medical Oncology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
    Cancer 91:90-100. 2001
  3. ncbi Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin
    A A Garcia
    1University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Anticancer Drugs 12:505-11. 2001
  4. ncbi Platinums: extending their therapeutic spectrum
    F M Muggia
    New York University School of Medicine, NY, NY 10016, USA
    J Chemother 16:77-82. 2004
  5. ncbi Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies
    J Szebeni
    Walter Reed Army Institute of Research, Silver Spring, MD, USA
    J Liposome Res 12:165-72. 2002
  6. ncbi Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions
    A Chanan-Khan
    Kaplan Comprehensive Cancer Center, New York University, New York, NY, USA
    Ann Oncol 14:1430-7. 2003
  7. ncbi Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132
    F M Muggia
    NYU School of Medicine and Cancer Institute, New York, NY 10016, USA
    Int J Gynecol Cancer 13:156-62. 2003
  8. ncbi 'Retarded pharmaceuticals' assuming a clinical role
    F M Muggia
    Onkologie 27:437-8. 2004
  9. ncbi Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
    A L Hamilton
    New York University School of Medicine, New York, NY, USA
    J Clin Oncol 23:6107-16. 2005

Collaborators

  • R T Koda
  • J D Hainsworth
  • A A Garcia
  • L Zhou
  • F A Greco
  • Jean M Adams
  • Tito Fojo
  • D P Ryan
  • L Liebes
  • A Chanan-Khan
  • J Szebeni
  • A L Hamilton
  • C R Alving
  • S Savay
  • T Safra
  • J Boyden
  • A Chachoua
  • J W Clark
  • R Garcia-Carbonero
  • A Zeleniuch-Jacquotte
  • J Wright
  • V Soma
  • P Elliott
  • N Kinchla
  • H Yee
  • J P Eder
  • A C Pavlick
  • K Farrell
  • N M Rafique
  • G Storm
  • Y Barenholz
  • L Baranyi
  • J Milosevits
  • P Laverman
  • J M Metselaar
  • R Cohen
  • R Bunger
  • S Jeffers
  • L Muderspach
  • S Groshen
  • D D Tsao-Wei
  • C P Morrow
  • A Burnett
  • L Roman

Detail Information

Publications9

  1. ncbi Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation
    F M Muggia
    Department of Radiology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
    J Clin Oncol 15:987-93. 1997
    ..Liposomal doxorubicin was selected as a result of its superior activity against ovarian cancer xenografts relative to free doxorubicin and activity in refractory ovarian cancer patients that was noted during the phase I study...
  2. ncbi Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome
    T Safra
    Department of Medical Oncology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
    Cancer 91:90-100. 2001
    ..The role of this treatment in combination with other effective drugs should be explored in both previously treated and untreated patients with ovarian carcinoma...
  3. ncbi Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin
    A A Garcia
    1University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Anticancer Drugs 12:505-11. 2001
    ..29 +/- 10.88 ml/min. Neutropenia represented the dose-limiting toxicity. We conclude that i.p. FUdR and LV in combination with i.v. HU is well tolerated. The addition of systemic HU increased the incidence of myelosuppression...
  4. ncbi Platinums: extending their therapeutic spectrum
    F M Muggia
    New York University School of Medicine, NY, NY 10016, USA
    J Chemother 16:77-82. 2004
    ..Both new drug development and mechanistic studies with established drugs should lead to the next generation of clinical studies with platinum compounds, and their integration with emerging 'targeted therapies'...
  5. ncbi Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies
    J Szebeni
    Walter Reed Army Institute of Research, Silver Spring, MD, USA
    J Liposome Res 12:165-72. 2002
    ..These data suggest that liposome-induced HSRs in susceptible individuals may be due to C activation, which, in turn, is due to the presence of negatively charged PEG-PE in these vesicles...
  6. ncbi Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions
    A Chanan-Khan
    Kaplan Comprehensive Cancer Center, New York University, New York, NY, USA
    Ann Oncol 14:1430-7. 2003
    ..Previous in vitro and animal studies indicated that activation of the complement (C) system might play a causal role in the process, a proposal that has not been tested in humans to date...
  7. ncbi Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132
    F M Muggia
    NYU School of Medicine and Cancer Institute, New York, NY 10016, USA
    Int J Gynecol Cancer 13:156-62. 2003
    ..Mathematical modeling and recent positive results in breast cancer adjuvant therapy support the use of 'dose-dense' strategies, and these should be considered in the design of future trials in ovarian cancer...
  8. ncbi 'Retarded pharmaceuticals' assuming a clinical role
    F M Muggia
    Onkologie 27:437-8. 2004
  9. ncbi Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
    A L Hamilton
    New York University School of Medicine, New York, NY, USA
    J Clin Oncol 23:6107-16. 2005
    ..We performed a phase I study of a day (D) 1 and D4 bortezomib administration once every 2 weeks to determine the recommended phase II dose and toxicity profile, and the extent of 20S proteasome inhibition obtained...